N/A
Completed N=33
Community Pharmacists Vaccinate Against Cancer
Human Papillomavirus Vaccines
Source: ClinicalTrials.gov NCT04072159 ↗
Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Nov 2021
Primary outcomePrimary: Number of Participants Who Completed HPV Vaccine Series(Preliminary Efficacy) — 8; 11 Participants
Summary
Latino and African American populations have a higher rate of human papillomavirus (HPV) vaccine initiation; however, they have a significantly less likelihood of completing the vaccine series. Pharmacists are licensed to vaccinate against the HPV virus. However, they are less likely to administer the vaccine. Although past research has recommended incorporating pharmacists to increase adolescent vaccination, no intervention studies, to our knowledge, have tested a healthcare delivery model that incorporates pharmacists to complete the HPV vaccine series. The aims of this pilot randomized controlled trial are to 1) determine the preliminary efficacy of an intervention to increase HPV vaccine series completion with the community pharmacist vs. with the primary care provider among racially/ethnically diverse participants, and 2) assess perceived intervention feasibility and acceptability of the intervention among intervention participants and primary care clinic staff.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Completed HPV Vaccine Series(Preliminary Efficacy) |
8; 11 | — |
| SECONDARY Intervention Feasibility in Participant Enrollment/Study Completion |
8 | — |
Eligibility Criteria
Inclusion Criteria
- Caregivers of a child between ages 9-18 who has either not received any HPV vaccine doses or has received only initial HPV dose
- Receives care at Adelante Healthcare Mesa
- Fluent in English and/or Spanish
- Willing to provide informed consent
Exclusion Criteria
- Caregivers whose child has completed additional HPV vaccine doses
- Child is over age 18 years (no caregiver consent needed)
Data sourced from ClinicalTrials.gov (NCT04072159). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.